Which medication is given as a daily injection to reduce the hypermetabolic response post-burn injury?

Recombinant human growth hormone is administered as a daily injection to effectively reduce the hypermetabolic response that occurs following a burn injury. This medication is known to promote an increase in lean body mass, stimulate protein synthesis, and encourage the utilization of fat stores for energy. These actions help mitigate the excessive metabolic demands that patients experience after burns, which can lead to complications such as delayed healing and increased risk of infection.

Burn injuries elicit a state of hypermetabolism characterized by increased energy expenditure and protein catabolism. This hypermetabolic state can significantly hinder recovery, requiring comprehensive management strategies. The role of recombinant human growth hormone becomes crucial as it aids in achieving metabolic balance and supports wound healing processes. Its administration is aligned with the goal of optimizing recovery outcomes for burn patients by addressing these specific post-injury metabolic needs.

Other options, while they have their own clinical applications, do not specifically target the hypermetabolic response following burn injuries. For instance, insulin regulates blood glucose levels but does not inherently address the metabolic increase caused by burns. Corticosteroids, although they have anti-inflammatory effects, do not have a direct role in managing hypermetabolism related to burns. Antibiotics are critical in preventing or treating infections but do not influence the